MacroGenics（M55）株式概要マクロジェニックス社は、臨床段階にあるバイオ医薬品会社で、米国においてがん治療用の抗体ベースの治療薬の発見、開発、製造、商業化を行なっている。 詳細M55 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長1/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間8.76%増加すると予測されています リスク分析今後3年間の収益は年平均12.8%減少すると予測されている。 現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るM55 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,493 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,493 investors already sharing narrativesYour Fair ValueCHF Current PriceCHF 3.0172.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-217m239m2016201920222025202620282031Revenue US$239.1mEarnings US$42.4mAdvancedSet Fair ValueView all narrativesMacroGenics, Inc. 競合他社Santhera Pharmaceuticals HoldingSymbol: SWX:SANNMarket cap: CHF 212.1mBasilea PharmaceuticaSymbol: SWX:BSLNMarket cap: CHF 643.3mMindMaze Therapeutics HoldingSymbol: SWX:MMTXMarket cap: CHF 30.4mIdorsiaSymbol: SWX:IDIAMarket cap: CHF 1.6b価格と性能株価の高値、安値、推移の概要MacroGenics過去の株価現在の株価US$3.0152週高値US$052週安値US$0ベータ1.181ヶ月の変化-19.06%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-5.81%最新ニュースお知らせ • Jul 24MacroGenics, Inc. Provides Clinical Update on Ongoing Phase 1 Study for MGC026MacroGenics, Inc. provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and preliminary tumor-specific cohort results at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23-27, 2026, in Madrid, Spain. The dose escalation portion of the study evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks (q3W) and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg q3W is being further evaluated in four tumor-specific cohorts: recurrent or metastatic SCCHN, endometrial cancer, melanoma, and soft tissue sarcoma. The study is active at clinical sites in the United States, Australia and the United Kingdom. The SCCHN cohort employs a Simon’s two-stage design, with a planned enrollment target of 40 patients. MacroGenics is currently enrolling SCCHN patients in Stage 2 after meeting the pre-specified response threshold in Stage 1. Enrollment in the other three cohorts continues as planned. As of July 8, 2026, a total of 74 patients had been enrolled across the dose escalation and ongoing cohort expansion portions of the study. As of this date, there were no cases of interstitial lung disease or ocular toxicity reported, and evidence of anti-tumor activity was observed across several indications.お知らせ • Jul 11Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026MACROGENICS, INC. reported that on July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors of her decision to resign from the Board, effective September 1, 2026. Dr. Ferrante's decision was for personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices.お知らせ • Jul 03Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX).Bora Biologics USA, LLC entered into a definitive agreement to acquire Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) for approximately $130 million on May 11, 2026. A cash consideration of $122.5 million will be paid at closing, subject to customary adjustments, including for working capital and indebtedness. Additionally, the agreement provides for up to $5 million of potential additional post-closing cash payments to MacroGenics upon achievement of certain manufacturing milestones by the CDMO Operations and professional development program services to be performed by the CDMO Operations in 2027 and 2028. Anticipated workforce reduction of160 positions, including140 employees expected to transfer to Bora. The transaction has been approved by the Boards of Directors of MacroGenics and Bora and is expected to close in the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions. Moelis & Company LLC acted as financial advisor and Covington & Burling LLP and Sidley Austin LLP acted as legal advisor for MacroGenics, Inc. Jones Day acted as legal advisor for Bora Biologics USA, LLC. Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) on July 2, 2026.Board Change • Jun 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 23MacroGenics Receives Regulatory Milestone Payment From Sanofi Following FDA Accelerated Approval Of TZIELD To Delay Decline In Endogenous Insulin Production In Children Aged Eight To 17 Years With Stage 3 Type 1 DiabetesMacroGenics, Inc. announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes. Under the terms of MacroGenics’ agreement with Sanofi, the recent FDA approval triggered a $24.5 million regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305 million in additional milestone payments and retains the right to receive a single-digit royalty on global net sales above a specified annual threshold. TZIELD (teplizumab) is a CD3-directed monoclonal antibody. TZIELD is the first disease-modifying therapy in autoimmune T1D; it was approved in the U.S. in November 2022 to delay the onset of stage 3 T1D in adults and children eight years and older diagnosed with stage 2 T1D. In April 2026, the FDA expanded this indication to include children aged one year and above. TZIELD is also approved in adults and children eight years and older with stage 2 in the UK, the EU (under the name TEIZEILD), China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil and Switzerland. In June 2026, the FDA approved TZIELD to delay the onset of Stage 3 T1D in adults.Board Change • Jun 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • Jul 24MacroGenics, Inc. Provides Clinical Update on Ongoing Phase 1 Study for MGC026MacroGenics, Inc. provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and preliminary tumor-specific cohort results at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23-27, 2026, in Madrid, Spain. The dose escalation portion of the study evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks (q3W) and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg q3W is being further evaluated in four tumor-specific cohorts: recurrent or metastatic SCCHN, endometrial cancer, melanoma, and soft tissue sarcoma. The study is active at clinical sites in the United States, Australia and the United Kingdom. The SCCHN cohort employs a Simon’s two-stage design, with a planned enrollment target of 40 patients. MacroGenics is currently enrolling SCCHN patients in Stage 2 after meeting the pre-specified response threshold in Stage 1. Enrollment in the other three cohorts continues as planned. As of July 8, 2026, a total of 74 patients had been enrolled across the dose escalation and ongoing cohort expansion portions of the study. As of this date, there were no cases of interstitial lung disease or ocular toxicity reported, and evidence of anti-tumor activity was observed across several indications.お知らせ • Jul 11Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026MACROGENICS, INC. reported that on July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors of her decision to resign from the Board, effective September 1, 2026. Dr. Ferrante's decision was for personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices.お知らせ • Jul 03Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX).Bora Biologics USA, LLC entered into a definitive agreement to acquire Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) for approximately $130 million on May 11, 2026. A cash consideration of $122.5 million will be paid at closing, subject to customary adjustments, including for working capital and indebtedness. Additionally, the agreement provides for up to $5 million of potential additional post-closing cash payments to MacroGenics upon achievement of certain manufacturing milestones by the CDMO Operations and professional development program services to be performed by the CDMO Operations in 2027 and 2028. Anticipated workforce reduction of160 positions, including140 employees expected to transfer to Bora. The transaction has been approved by the Boards of Directors of MacroGenics and Bora and is expected to close in the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions. Moelis & Company LLC acted as financial advisor and Covington & Burling LLP and Sidley Austin LLP acted as legal advisor for MacroGenics, Inc. Jones Day acted as legal advisor for Bora Biologics USA, LLC. Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) on July 2, 2026.Board Change • Jun 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 23MacroGenics Receives Regulatory Milestone Payment From Sanofi Following FDA Accelerated Approval Of TZIELD To Delay Decline In Endogenous Insulin Production In Children Aged Eight To 17 Years With Stage 3 Type 1 DiabetesMacroGenics, Inc. announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes. Under the terms of MacroGenics’ agreement with Sanofi, the recent FDA approval triggered a $24.5 million regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305 million in additional milestone payments and retains the right to receive a single-digit royalty on global net sales above a specified annual threshold. TZIELD (teplizumab) is a CD3-directed monoclonal antibody. TZIELD is the first disease-modifying therapy in autoimmune T1D; it was approved in the U.S. in November 2022 to delay the onset of stage 3 T1D in adults and children eight years and older diagnosed with stage 2 T1D. In April 2026, the FDA expanded this indication to include children aged one year and above. TZIELD is also approved in adults and children eight years and older with stage 2 in the UK, the EU (under the name TEIZEILD), China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil and Switzerland. In June 2026, the FDA approved TZIELD to delay the onset of Stage 3 T1D in adults.Board Change • Jun 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.株主還元M55CH BiotechsCH 市場7D-2.5%-2.8%0.4%1Yn/a19.7%17.4%株主還元を見る業界別リターン: M55がSwiss Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: M55 Swiss市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is M55's price volatile compared to industry and market?M55 volatilityM55 Average Weekly Movementn/aBiotechs Industry Average Movement7.5%Market Average Movement4.1%10% most volatile stocks in CH Market7.8%10% least volatile stocks in CH Market2.2%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間のM55のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2000293Eric Risserwww.macrogenics.comマクロジェニックス社は、臨床段階にあるバイオ医薬品企業で、米国においてがん治療用の抗体ベースの治療薬の発見、開発、製造、商業化を行なっている。同社の製品パイプラインには、チェックポイント阻害薬PD-1とCTLA-4を標的とする二重特異性DART分子であるlorigerlimabがあり、mCRPCとドセタキセルの治療薬として第2相臨床試験中であるほか、プラチナ製剤抵抗性卵巣がんと明細胞性婦人科がんの治療薬として第1相臨床試験を終了している；B7-H3を標的とし、新規トポイソメラーゼI阻害剤（TOP1i）ベースのリンカーペイロードを送達するADCであるMGC026、固形癌の治療のためにADAM9を標的とし、新規TOP1iベースのリンカーペイロードを送達する抗体薬物複合体（ADC）であるMGC028（第1相臨床試験中）、複数の固形癌に発現する非公開抗原を標的とするADC分子であるMGC030（前臨床試験中）。また、T細胞エンゲイジャープログラムも開発中である。同社はTerSera Therapeutics LLC、Incyte Corporation、Gilead Sciences, Inc.と共同研究を行っている。マクロジェニックス社は2000年に設立され、メリーランド州ロックビルに本社を置いている。もっと見るMacroGenics, Inc. 基礎のまとめMacroGenics の収益と売上を時価総額と比較するとどうか。M55 基礎統計学時価総額CHF 194.23m収益（TTM）-CHF 56.88m売上高(TTM)CHF 126.98m1.5xP/Sレシオ-3.3xPER（株価収益率M55 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計M55 損益計算書（TTM）収益US$157.08m売上原価US$182.59m売上総利益-US$25.50mその他の費用US$44.85m収益-US$70.36m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.11グロス・マージン-16.24%純利益率-44.79%有利子負債／自己資本比率0%M55 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 09:55終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MacroGenics, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Peter LawsonBarclaysEtzer DaroutBarclaysStephen V. ByrneBofA Global Research15 その他のアナリストを表示
お知らせ • Jul 24MacroGenics, Inc. Provides Clinical Update on Ongoing Phase 1 Study for MGC026MacroGenics, Inc. provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and preliminary tumor-specific cohort results at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23-27, 2026, in Madrid, Spain. The dose escalation portion of the study evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks (q3W) and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg q3W is being further evaluated in four tumor-specific cohorts: recurrent or metastatic SCCHN, endometrial cancer, melanoma, and soft tissue sarcoma. The study is active at clinical sites in the United States, Australia and the United Kingdom. The SCCHN cohort employs a Simon’s two-stage design, with a planned enrollment target of 40 patients. MacroGenics is currently enrolling SCCHN patients in Stage 2 after meeting the pre-specified response threshold in Stage 1. Enrollment in the other three cohorts continues as planned. As of July 8, 2026, a total of 74 patients had been enrolled across the dose escalation and ongoing cohort expansion portions of the study. As of this date, there were no cases of interstitial lung disease or ocular toxicity reported, and evidence of anti-tumor activity was observed across several indications.
お知らせ • Jul 11Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026MACROGENICS, INC. reported that on July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors of her decision to resign from the Board, effective September 1, 2026. Dr. Ferrante's decision was for personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices.
お知らせ • Jul 03Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX).Bora Biologics USA, LLC entered into a definitive agreement to acquire Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) for approximately $130 million on May 11, 2026. A cash consideration of $122.5 million will be paid at closing, subject to customary adjustments, including for working capital and indebtedness. Additionally, the agreement provides for up to $5 million of potential additional post-closing cash payments to MacroGenics upon achievement of certain manufacturing milestones by the CDMO Operations and professional development program services to be performed by the CDMO Operations in 2027 and 2028. Anticipated workforce reduction of160 positions, including140 employees expected to transfer to Bora. The transaction has been approved by the Boards of Directors of MacroGenics and Bora and is expected to close in the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions. Moelis & Company LLC acted as financial advisor and Covington & Burling LLP and Sidley Austin LLP acted as legal advisor for MacroGenics, Inc. Jones Day acted as legal advisor for Bora Biologics USA, LLC. Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) on July 2, 2026.
Board Change • Jun 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 23MacroGenics Receives Regulatory Milestone Payment From Sanofi Following FDA Accelerated Approval Of TZIELD To Delay Decline In Endogenous Insulin Production In Children Aged Eight To 17 Years With Stage 3 Type 1 DiabetesMacroGenics, Inc. announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes. Under the terms of MacroGenics’ agreement with Sanofi, the recent FDA approval triggered a $24.5 million regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305 million in additional milestone payments and retains the right to receive a single-digit royalty on global net sales above a specified annual threshold. TZIELD (teplizumab) is a CD3-directed monoclonal antibody. TZIELD is the first disease-modifying therapy in autoimmune T1D; it was approved in the U.S. in November 2022 to delay the onset of stage 3 T1D in adults and children eight years and older diagnosed with stage 2 T1D. In April 2026, the FDA expanded this indication to include children aged one year and above. TZIELD is also approved in adults and children eight years and older with stage 2 in the UK, the EU (under the name TEIZEILD), China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil and Switzerland. In June 2026, the FDA approved TZIELD to delay the onset of Stage 3 T1D in adults.
Board Change • Jun 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 24MacroGenics, Inc. Provides Clinical Update on Ongoing Phase 1 Study for MGC026MacroGenics, Inc. provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and preliminary tumor-specific cohort results at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23-27, 2026, in Madrid, Spain. The dose escalation portion of the study evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks (q3W) and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg q3W is being further evaluated in four tumor-specific cohorts: recurrent or metastatic SCCHN, endometrial cancer, melanoma, and soft tissue sarcoma. The study is active at clinical sites in the United States, Australia and the United Kingdom. The SCCHN cohort employs a Simon’s two-stage design, with a planned enrollment target of 40 patients. MacroGenics is currently enrolling SCCHN patients in Stage 2 after meeting the pre-specified response threshold in Stage 1. Enrollment in the other three cohorts continues as planned. As of July 8, 2026, a total of 74 patients had been enrolled across the dose escalation and ongoing cohort expansion portions of the study. As of this date, there were no cases of interstitial lung disease or ocular toxicity reported, and evidence of anti-tumor activity was observed across several indications.
お知らせ • Jul 11Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026MACROGENICS, INC. reported that on July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors of her decision to resign from the Board, effective September 1, 2026. Dr. Ferrante's decision was for personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices.
お知らせ • Jul 03Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX).Bora Biologics USA, LLC entered into a definitive agreement to acquire Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) for approximately $130 million on May 11, 2026. A cash consideration of $122.5 million will be paid at closing, subject to customary adjustments, including for working capital and indebtedness. Additionally, the agreement provides for up to $5 million of potential additional post-closing cash payments to MacroGenics upon achievement of certain manufacturing milestones by the CDMO Operations and professional development program services to be performed by the CDMO Operations in 2027 and 2028. Anticipated workforce reduction of160 positions, including140 employees expected to transfer to Bora. The transaction has been approved by the Boards of Directors of MacroGenics and Bora and is expected to close in the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions. Moelis & Company LLC acted as financial advisor and Covington & Burling LLP and Sidley Austin LLP acted as legal advisor for MacroGenics, Inc. Jones Day acted as legal advisor for Bora Biologics USA, LLC. Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice (GMP) Drug Substance Manufacturing Operations of MacroGenics, Inc. (NasdaqGS:MGNX) on July 2, 2026.
Board Change • Jun 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 23MacroGenics Receives Regulatory Milestone Payment From Sanofi Following FDA Accelerated Approval Of TZIELD To Delay Decline In Endogenous Insulin Production In Children Aged Eight To 17 Years With Stage 3 Type 1 DiabetesMacroGenics, Inc. announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration’s (FDA) accelerated approval of TZIELD (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes. Under the terms of MacroGenics’ agreement with Sanofi, the recent FDA approval triggered a $24.5 million regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305 million in additional milestone payments and retains the right to receive a single-digit royalty on global net sales above a specified annual threshold. TZIELD (teplizumab) is a CD3-directed monoclonal antibody. TZIELD is the first disease-modifying therapy in autoimmune T1D; it was approved in the U.S. in November 2022 to delay the onset of stage 3 T1D in adults and children eight years and older diagnosed with stage 2 T1D. In April 2026, the FDA expanded this indication to include children aged one year and above. TZIELD is also approved in adults and children eight years and older with stage 2 in the UK, the EU (under the name TEIZEILD), China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil and Switzerland. In June 2026, the FDA approved TZIELD to delay the onset of Stage 3 T1D in adults.
Board Change • Jun 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. CEO, President & Director Eric Risser was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
